Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Diamedica Therapeutics Inc (DMAC)

Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms ACCESS Newswire - Tue Apr 7, 6:00AM CDT

ORLANDO, FL / ACCESS Newswire / April 7, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming virtual...

CLDI : 0.2565 (-0.43%)
INAB : 1.3900 (-2.80%)
CNTB : 2.82 (+1.44%)
DMAC : 5.99 (-3.07%)
NSRX : 2.20 (-5.17%)
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights Business Wire - Mon Mar 30, 3:45PM CDT

Received Regulatory Approval from Health Canada Supporting Initiation of Phase 2 DM199 Study in Early-onset Preeclampsia. DM199...

DMAC : 5.99 (-3.07%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends. Barchart - Sun Mar 29, 4:00PM CDT

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 5.99 (-3.07%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends. Barchart - Sat Mar 28, 4:01PM CDT

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 5.99 (-3.07%)
Diamedica Has Been Quietly Running Its Trials. Monday, the Silence Ends. Barchart - Fri Mar 27, 4:02PM CDT

Barchart Research What to Expect from DMAC Earnings DMAC Generated March 27, 2026 Current Price $6.79 EPS Estimate $-0.17 Consensus Rating Strong Buy Average Move 7.13% Diamedica Has Been Quietly Running...

DMAC : 5.99 (-3.07%)
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 Business Wire - Mon Mar 23, 7:25AM CDT

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS),...

DMAC : 5.99 (-3.07%)
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia Business Wire - Thu Mar 5, 6:35AM CST

“No Objection Letter” from Health Canada enables initiation of Phase 2 DM199 study in early-onset preeclampsia DM199 Preeclampsia...

DMAC : 5.99 (-3.07%)
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences Business Wire - Tue Feb 24, 8:23AM CST

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today...

DMAC : 5.99 (-3.07%)
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Jan 16, 4:00PM CST

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today...

DMAC : 5.99 (-3.07%)
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA Business Wire - Thu Dec 18, 2025

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS),...

DMAC : 5.99 (-3.07%)

Barchart Exclusives

ConocoPhillips vs. EOG: 1 of These Energy Stocks Is Cheaper and Pays You More. Which One? Barchart - Fri Apr 10, 6:00PM CDT
ConocoPhillips and EOG are both winning energy stocks, but one stands out on scale while the other looks cheaper and stronger for income. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.